Domestic Pharma Firms

Companies with higher exports are likely to benefit due to the rupee depreciation against the US dollar.

Lack of fresh prescriptions drags growth in acute therapies

According to Icra research, domestic API manufacturers have an inventory of one-two months

Volume growth in the domestic market had turned negative in the last two months but was a big growth driver in July

Domestic companies are investing heavily to build a pipeline of specialty and complex drugs

Domestic pharma companies enjoy a 77% share of the Indian pharma market, and this share has been consistently above 74% in the past four years or so